(0.25%) 5 144.50 points
(0.27%) 38 546 points
(0.35%) 17 909 points
(-0.82%) $83.16
(1.30%) $1.948
(-0.12%) $2 344.50
(1.22%) $27.59
(0.72%) $928.70
(-0.28%) $0.932
(-0.28%) $10.99
(-0.40%) $0.797
(0.85%) $92.66
0.00% € 0.0410
Live Chart Being Loaded With Signals
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...
Stats | |
---|---|
Dzisiejszy wolumen | 10.21M |
Średni wolumen | 4.35M |
Kapitalizacja rynkowa | 0.00 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.187 |
ATR14 | €0 (0.00%) |
NOXXON Pharma NV Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
NOXXON Pharma NV Finanse
Annual | 2021 |
Przychody: | €0.00 |
Zysk brutto: | €0.00 (0.00 %) |
EPS: | €-45.99 |
FY | 2021 |
Przychody: | €0.00 |
Zysk brutto: | €0.00 (0.00 %) |
EPS: | €-45.99 |
FY | 2020 |
Przychody: | €0.00 |
Zysk brutto: | €0.00 (0.00 %) |
EPS: | €-32.16 |
FY | 2019 |
Przychody: | €0.00 |
Zysk brutto: | €-1.03M (0.00 %) |
EPS: | €-7.72 |
Financial Reports:
No articles found.
NOXXON Pharma NV
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej